NASDAQ: AVXL

Neurological Disorders

We are dedicated to advancing brain health by developing innovative oral medicines designed to improve patients’ lives.

Innovative Solutions, Meaningful Impact

From neurodegenerative diseases to rare genetic disorders, our approach is driven by cutting-edge science, a deep understanding of the complexities of these diseases, and a relentless dedication to improving lives.

Through our innovative therapies, we aim to restore hope, preserve quality of life, and transform the standard of care for these conditions. Each of the diseases we focus on represents a unique opportunity to make a meaningful difference for patients and their loved ones.

Alzheimer’s Disease (AD) is a progressive and irreversible brain disorder that slowly erodes memory, cognitive abilities, and essential functions for independent living. It is the most common form of dementia and poses significant emotional, physical, and financial challenges for individuals and their families.
Parkinson’s Disease (PD) is a progressive neurological disorder that affects movement, balance, and coordination. It is primarily caused by the degeneration of dopamine-producing neurons in the brain, leading to motor symptoms such as tremors, stiffness, and slowed movement.
Rett Syndrome (RS) is a rare neurological disorder that primarily affects girls, causing severe cognitive, motor, and communication impairments. It is typically diagnosed in early childhood and is often marked by a loss of previously acquired skills.
A stroke is a medical emergency that occurs when blood flow to the brain is interrupted, either due to a blocked artery (ischemic stroke) or a ruptured blood vessel (hemorrhagic stroke). This disruption leads to brain cell death, resulting in physical, cognitive, and emotional impairments.
Pain is a complex and multifaceted experience that serves as the body’s warning system for injury or illness. While acute pain often resolves with treatment, chronic pain can persist for months or years, significantly impacting an individual’s quality of life.
Infantile spasms are a rare and severe form of epilepsy that typically begin in infancy. These spasms are characterized by sudden, jerking movements and are often accompanied by developmental delays and abnormal brain wave patterns, requiring immediate medical attention.
Frontotemporal Dementia (FTD) is a group of neurodegenerative disorders that primarily affect the frontal and temporal lobes of the brain, leading to changes in behavior, personality, language, and movement. It is a major cause of dementia in individuals under the age of 65.
Fragile X Syndrome (FXS) is the most common inherited cause of intellectual disability and developmental delays. It is a genetic condition that affects learning, behavior, and social interactions, often presenting alongside physical and emotional challenges.
Depression is a common yet serious mental health condition that affects how a person feels, thinks, and handles daily activities. It goes beyond temporary sadness, often disrupting an individual’s ability to function and diminishing their overall quality of life.
Angelman Syndrome is a rare genetic disorder that affects the nervous system, leading to developmental delays, movement and balance issues, minimal to no speech, and frequent seizures. Despite these challenges, individuals with Angelman Syndrome often exhibit a happy demeanor, with frequent smiling and laughter.
Schizophrenia is a chronic mental health condition that affects thought processes, perceptions, and behavior, often causing delusions, hallucinations, and difficulties with social interaction.

Support and Trusted Resources

Living with neurological disease can feel overwhelming, but patients and caregivers do not have to navigate it alone. The following organizations provide education, advocacy, and community support:

Alzheimer’s Research and Support Organizations

Utilize resources from organizations like the Alzheimer’s Association at www.alz.org, which provide updates on treatment advances, professional caregiver support, and educational materials.

Michael J. Fox Foundation

Utilize resources from organizations like the Michael J. Fox Foundation, which provide research updates, patient and caregiver education, and opportunities to engage with Parkinson’s disease research.

Clinical Trial Information

Review detailed trial data and protocol information for the recently completed blarcamesine open-label extension Phase IIb/III study available at ClinicalTrials.gov.

You are about to leave our website

By clicking “Continue,” you acknowledge that you are leaving the Anavex Life Sciences website and will be redirected to a third-party website operated by NASDAQ or its affiliates.

Anavex Life Sciences does not own, control, maintain, or endorse the content on third-party websites and is not responsible for their accuracy, completeness, or reliability. Any information available through this link is provided by third parties and does not represent the views, opinions, forecasts, or predictions of Anavex Life Sciences or its management.

The linked content is provided for informational purposes only and does not constitute investment advice or an offer to buy or sell securities. Investors should rely on their own independent judgment and consult professional advisors before making any investment decisions.